Another experimental vaccine shows promising data on its effectiveness during trials.
AstraZeneca said its vaccine candidate is up to 90% effective and was studied over two different dosing regimens.
The one showed to be 90% effective, participants received a half-dose, then a full dose at least one month apart.
Now when combined with results of the second dosing regimen, the vaccine candidate has an average efficacy rate of 70%.
AstraZeneca is the third major company now to report a high effective rate for its potential vaccine.
Just last week, Pfizer and Moderna reported its vaccines were close to 95% effective.
